300 related articles for article (PubMed ID: 33968657)
1. Whole blood
Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
[TBL] [Abstract][Full Text] [Related]
2. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
5. Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Cho H; Byun SS; Son NH; Chung JI; Seo WI; Lee CH; Morgan TM; Han KH; Chung JS
Clin Cancer Res; 2024 May; 30(9):1788-1800. PubMed ID: 38587547
[TBL] [Abstract][Full Text] [Related]
6. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
7. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy.
Lee CU; Cho E; Lee J; Lim JE; Chung JH; Song W; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
Eur Urol Focus; 2023 Jan; 9(1):89-95. PubMed ID: 36167777
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
12. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
13. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
14. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
[TBL] [Abstract][Full Text] [Related]
15. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies.
Wenzel M; Preisser F; Hoeh B; Schroeder M; Würnschimmel C; Steuber T; Heinzer H; Banek S; Ahrens M; Becker A; Karakiewicz PI; Chun FKH; Kluth LA; Mandel P
Front Oncol; 2021; 11():659135. PubMed ID: 33968764
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
Li H; Zhang Y; Li D; Ma X; Xu K; Ding B; Li H; Wang Z; Ouyang W; Long G; Zeng J; Liu H; Yan L; Zhang Y; Liu Z; Guan W; Hu Z; Liu C; Wan J; Wang G; Pu X; Zhang M; Guo L; An R; Qi J; Guo A; Ye Z; Liu J; Zhang X; Xu H
Eur Urol; 2021 Jun; 79(6):879-886. PubMed ID: 33579577
[TBL] [Abstract][Full Text] [Related]
19.
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Mokoala K; Reed J; Maseremule L; Ndlovu H; Hlongwa K; Maes A; Morgenstern A; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2210-2218. PubMed ID: 36864360
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
